Home > Research Programs > Experimental Therapeutics Group
Experimental Therapeutics Group
Strategic Goals
- Discovering novel mechanisms of anti-HER2 therapy resistance
- Identifying mechanisms of resistance to PI3K/Akt/mTOR inhibitors
- Hypothesis-based testing of new therapeutic strategies
Current objectives
- Translate to clinical practice the use of CDK2 and Hsp90 inhibitors
- Study the efficacy of novel Akt/mTOR inhibitors
- Predict genes/pathways responsible for resistance to PI3K/Akt/mTOR inhibitors
- Study new therapeutic combinations such as PI3K/Akt/mTOR inhibitors with MEK inhibitors or mTOR inhibitors with anti-IGF-IR agents.
- Develop preclinical models based on tumor explants in immunocompromised mice.
Team
Staff Scientist
- Maurizio Scaltriti PhD mscaltriti(ELIMINAR)@vhio.net
Medical Oncologists
- Josep Tabernero MD jtabernero(ELIMINAR)@vhio.net
- Jordi Rodon MD jrodon(ELIMINAR)@vhio.net
Post-doctoral Fellows
- Violeta Serra PhD vserra(ELIMINAR)@vhio.net
- Yasir Ibrahim PhD
- Celina Garcia PhD
Technicians
- Marta Guzman
- Olga Rodriguez
- Pilar Anton
- Maite Calvo
- Judith Grueso
- Patricia Cozar
Publications
- Tabernero J, Ciardiello F, Rivera F, Rodriguez-Braun E, Ramos FJ, Martinelli E, Vega-Villegas ME, Roselló S, Liebscher S, Kisker O, Macarulla T, Baselga J, Cervantes A. Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study. Ann. Oncol. 2010 Jul; 21(7): 1537-45
- Ciruelos EM, Cortes J, Cortés-Funes H, Mayordomo JI, Bermejo B, Ojeda B, García E, Rodríguez CA, Muñoz M, Gómez P, Manso L, Andrés R, Lluch A, Saura C, Mendiola C, Baselga J. Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial). Ann. Oncol. 2010 Jul; 21(7): 1442-7
- Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010 Jan; 11(1): 21-8
- Chandarlapaty S, Scaltriti M, Angelini P, Ye Q, Guzman M, Hudis CA, Norton L, Solit DB, Arribas J, Baselga J, Rosen N. Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth. Oncogene 2010 Jan; 29(3): 325-34
- Ellis MJ, Lin L, Crowder R, Tao Y, Hoog J, Snider J, Davies S, DeSchryver K, Evans DB, Steinseifer J, Bandaru R, Liu W, Gardner H, Semiglazov V, Watson M, Hunt K, Olson J, Baselga J. Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer. Breast Cancer Res. Treat. 2010 Jan; 119(2): 379-90
